GLSI Greenwich LifeSciences, Inc.
Nasdaq · SEC CIK 1799788 · EDGAR
- Bought, last 12 months
- $586.3K 11 purchases by 1 insiders
- Sold, last 12 months
- $0 0 sales by 0 insiders
- Filings on record
- 118 since 2021-12-16, latest 2026-07-30 06:05
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Patel Snehal | CEO, CFO, Dir, 10% | $586.3K | — |
Transactions 106
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-01-14 | 2022-01-13 | GLSI | Daugherty Frank Joseph | Chief Medical Off, Dir | P - Purchase | $19.99 | +1,000 | 89.1K | +1% | +$20.0K | |
| 2022-01-14 | 2022-01-13 | GLSI | Thompson Jaye | VP Clinical Reg. Affairs | P - Purchase | $19.99 | +1,000 | 254.0K | +0.4% | +$20.0K | |
| 2022-01-04 | 2022-01-03 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $23.82 | +2,050 | 1.19M | +0.2% | +$48.8K | |
| 2021-12-16 | 2021-12-14 | GLSI | Daugherty Frank Joseph | Chief Medical Off, Dir | P - Purchase | $26.99 | +1,111 | 88.1K | +1% | +$30.0K | |
| 2021-12-16 | 2021-12-14 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $27.17 | +1,840 | 1.19M | +0.2% | +$50.0K | |
| 2021-12-16 | 2021-12-14 | GLSI | McWilliams David | Dir | P - Purchase | $27.56 | +200 | 620.3K | +0.0% | +$5,512 |
Purchase Sale Sale after option exercise All abbreviations